Ignite Creation Date:
2024-05-06 @ 8:55 AM
Last Modification Date:
2024-10-26 @ 12:07 PM
Study NCT ID:
NCT02857270
Status:
COMPLETED
Last Update Posted:
2022-11-22
First Post:
2016-08-03
Brief Title:
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With AdvancedMetastatic Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 1 Study of an ERK12 Inhibitor LY3214996 Administered Alone or in Combination With Other Agents in Advanced Cancer
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of an extracellular signal regulated kinase ERK12 inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-001907-21 | EUDRACT_NUMBER | Eli Lilly and Company | None |
| I8S-MC-JUAB | OTHER | None | None |